Profile data is unavailable for this security.
About the company
Tenax Therapeutics, Inc. is a Phase 3 development-stage pharmaceutical company. The Company is focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical needs. The Company's products include TNX-201 (oral enteric coated imatinib) and TNX-103 (oral levosimendan). The Company is developing dosing and a formulation of imatinib mesylate, a kinase inhibitor for the treatment of pulmonary arterial hypertension (PAH). The Company’s other programs include TNX-101 (IV), TNX-102 (subcutaneous) and TNX-103 (oral) levosimendan. Levosimendan is a calcium sensitizer/K-ATP activator developed for intravenous use in hospitalized patients with acutely decompensated heart failure. The Company has completed the Phase II trial of levosimendan in patients with PH and heart failure with preserved ejection fraction (HFpEF).
- Revenue in USD (TTM)0.00
- Net income in USD-7.71m
- Incorporated2008
- Employees5.00
- LocationTenax Therapeutics Inc101 GLEN LENNOX DRIVE, SUITE 300CHAPEL HILL 27517United StatesUSA
- Phone+1 (919) 855-2100
- Fax+1 (302) 655-5049
- Websitehttp://www.tenaxthera.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Enveric Biosciences Inc | 0.00 | -17.46m | 7.15m | 7.00 | -- | 1.37 | -- | -- | -8.15 | -8.15 | 0.00 | 0.7142 | 0.00 | -- | -- | 0.00 | -144.99 | -104.94 | -207.98 | -156.88 | -- | -- | -- | -243.54 | -- | -- | 0.00 | -- | -- | -- | 7.14 | -- | -- | -- |
| Pulmatrix Inc | 7.30m | -14.12m | 7.16m | 22.00 | -- | 0.3978 | -- | 0.9809 | -3.87 | -3.87 | 2.00 | 4.93 | 0.1948 | -- | 6.56 | 331,727.30 | -37.70 | -46.91 | -42.80 | -58.12 | -- | -- | -193.49 | -238.04 | -- | -- | 0.00 | -- | 20.21 | 116.62 | 25.03 | -- | 104.29 | -- |
| Kazia Therapeutics Ltd (ADR) | 14.91k | -13.52m | 7.17m | 12.00 | -- | 0.7789 | -- | 480.98 | -0.8203 | -0.8203 | 0.0008 | 0.3492 | 0.0007 | -- | 73.97 | -- | -63.98 | -46.35 | -82.39 | -54.75 | -- | -- | -90,714.45 | -497.17 | -- | -- | 0.1297 | -- | 979.43 | -28.31 | 18.19 | -- | -- | -- |
| CV Sciences Inc | 16.00m | 3.10m | 7.18m | 42.00 | 2.13 | 2.45 | 2.15 | 0.4488 | 0.0206 | 0.0206 | 0.104 | 0.018 | 1.46 | 1.46 | 26.74 | 381,047.60 | 28.28 | -43.42 | 247.47 | -77.75 | 44.27 | 51.81 | 19.38 | -45.68 | 0.3733 | 13.68 | 0.0805 | -- | -1.24 | -19.80 | 133.96 | -20.87 | -- | -- |
| MyMD Pharmaceuticals Inc | 0.00 | -7.07m | 7.18m | 9.00 | -- | 0.3397 | -- | -- | -5.53 | -5.53 | 0.00 | 10.28 | 0.00 | -- | -- | 0.00 | -25.59 | -76.20 | -31.13 | -84.38 | -- | 7.64 | -- | -4,290.96 | -- | -- | 0.00 | -- | -- | -- | 49.15 | -- | -- | -- |
| Pasithea Therapeutics Corp | 0.00 | -15.51m | 7.21m | 8.00 | -- | 0.308 | -- | -- | -12.83 | -13.18 | 0.00 | 22.46 | 0.00 | -- | -- | 0.00 | -43.50 | -- | -46.44 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -32.23 | -- | -- | -- |
| Shuttle Pharmaceuticals Holdings Inc | 0.00 | -6.59m | 7.22m | 8.00 | -- | 1.70 | -- | -- | -0.441 | -0.441 | 0.00 | 0.2524 | 0.00 | -- | -- | 0.00 | -90.28 | -- | -104.75 | -- | -- | -- | -- | -- | -- | -49.56 | 0.1527 | -- | -- | -- | -112.71 | -- | -- | -- |
| Intelligent Bio Solutions Inc | 2.46m | -13.40m | 7.28m | 17.00 | -- | 0.096 | -- | 2.96 | -131.37 | -131.37 | 20.91 | 26.67 | 0.1831 | 2.41 | 9.09 | 144,726.50 | -99.96 | -80.65 | -157.15 | -224.84 | 20.90 | -- | -545.95 | -948.54 | 0.3864 | -- | 0.1602 | -- | 187.51 | 367.97 | -28.00 | -- | -- | -- |
| Tenax Therapeutics Inc | 0.00 | -7.71m | 7.52m | 5.00 | -- | 0.1414 | -- | -- | -33.51 | -33.51 | 0.00 | 27.15 | 0.00 | -- | -- | 0.00 | -102.20 | -199.16 | -159.72 | -285.64 | -- | -- | -- | -- | -- | -82.13 | 0.0583 | -- | -- | -- | 30.21 | -- | -- | -- |
| Trevena Inc | 3.13m | -40.29m | 7.56m | 23.00 | -- | -- | -- | 2.42 | -3.16 | -3.16 | 0.2611 | -0.4429 | 0.07 | 3.69 | -- | 135,869.60 | -90.25 | -55.93 | -110.38 | -66.35 | 46.56 | -- | -1,289.25 | -3,134.41 | 4.66 | -15.43 | 1.33 | -- | 847.61 | -11.43 | 24.93 | -- | -24.67 | -- |
| Plus Therapeutics Inc (USA) | 4.91m | -13.32m | 7.70m | 20.00 | -- | -- | -- | 1.57 | -4.51 | -4.51 | 1.57 | -0.3033 | 0.2787 | -- | -- | 245,650.00 | -75.54 | -59.18 | -210.10 | -133.04 | -- | -- | -271.04 | -470.45 | -- | -- | 1.51 | -- | 2,093.30 | -5.89 | 34.32 | -- | 3.77 | -- |
| Paranovus Entertainment Technology Ltd | 51.46m | -42.62m | 7.78m | 80.00 | -- | 0.7284 | -- | 0.1511 | -7.16 | -7.49 | 9.89 | 1.46 | 1.18 | 59.61 | 4.15 | 643,209.90 | -91.12 | -23.19 | -119.36 | -27.21 | 4.92 | 23.09 | -77.15 | -24.25 | 3.97 | -2,465.22 | 0.00 | -- | 9.68 | 9.80 | -45.84 | -- | -21.93 | -- |
| Universe Pharmaceuticals Inc | 32.31m | -6.16m | 7.84m | 225.00 | -- | 0.1972 | -- | 0.2426 | -1.70 | -1.70 | 8.91 | 10.91 | 0.5727 | 7.93 | 2.50 | 143,594.40 | -10.92 | 5.31 | -14.34 | 7.07 | 31.93 | 46.26 | -19.08 | 6.25 | 2.43 | -28.05 | 0.1218 | 0.00 | -19.52 | 2.53 | 29.46 | -- | -21.17 | -- |
| Cadrenal Therapeutics Inc | 0.00 | -8.36m | 7.85m | 4.00 | -- | 0.8304 | -- | -- | -0.7044 | -0.7044 | 0.00 | 0.5907 | 0.00 | -- | -- | 0.00 | -179.77 | -- | -234.22 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -24.47 | -- | -- | -- |
| Virios Therapeutics Inc | 0.00 | -5.30m | 7.92m | 4.00 | -- | -- | -- | -- | -0.283 | -0.283 | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 56.76 | -- | -- | -- |
| Hepion Pharmaceuticals Inc | 0.00 | -48.93m | 7.99m | 22.00 | -- | 1.26 | -- | -- | -12.41 | -12.41 | 0.00 | 1.51 | 0.00 | -- | -- | 0.00 | -124.91 | -61.43 | -150.17 | -68.82 | -- | -- | -- | -- | -- | -4,784.14 | 0.00 | -- | -- | -- | -7.92 | -- | -- | -- |
Data as of May 03 2024. Currency figures normalised to Tenax Therapeutics Inc's reporting currency: US Dollar USD
18.48%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Heights Capital Management, Inc.as of 20 Mar 2024 | 204.03k | 11.55% |
| S.H.N. Financial Investments Ltd.as of 20 Mar 2024 | 107.00k | 6.06% |
| Renaissance Technologies LLCas of 31 Dec 2023 | 4.25k | 0.24% |
| Corient Private Wealth LLCas of 31 Dec 2023 | 2.39k | 0.14% |
| The Vanguard Group, Inc.as of 31 Dec 2023 | 2.33k | 0.13% |
| Geode Capital Management LLCas of 31 Dec 2023 | 1.85k | 0.11% |
| Two Sigma Investments LPas of 31 Dec 2023 | 1.78k | 0.10% |
| SSgA Funds Management, Inc.as of 31 Dec 2023 | 1.19k | 0.07% |
| G1 Execution Services LLCas of 31 Dec 2023 | 952.00 | 0.05% |
| Citadel Securities LLCas of 31 Dec 2023 | 632.00 | 0.04% |
More ▼
Data from 31 Dec 2023 - 20 Mar 2024Source: FactSet Research Systems Inc.
